
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Research Report 2025(Status and Outlook)
Description
Report Overview
Neurological biomarkers for Alzheimer's and Parkinson's diseases are measurable biological indicators that aid in the early detection, diagnosis, and monitoring of these neurodegenerative disorders. These biomarkers include proteins (e.g., amyloid-beta, tau, alpha-synuclein), genetic markers, cerebrospinal fluid (CSF) analytes, neuroimaging signals (e.g., PET scans, MRI), and blood-based markers. Their role is critical in differentiating between disease subtypes, assessing progression, and evaluating therapeutic efficacy, particularly as precision medicine gains traction in neurology. The demand for reliable, non-invasive biomarkers is accelerating due to the rising global prevalence of neurodegenerative diseases, the limitations of clinical symptom-based diagnosis, and the need for objective measures in clinical trials. Advances in proteomics, genomics, and AI-driven data analysis are expanding the scope of biomarker discovery, though challenges remain in standardization, validation, and regulatory approval. The market is driven by increasing R&D investments, collaborations between pharmaceutical companies and diagnostic firms, and growing emphasis on early intervention strategies. However, high development costs, ethical concerns around genetic testing, and variability in biomarker sensitivity and specificity pose barriers to widespread adoption. North America and Europe dominate the market due to robust healthcare infrastructure, while Asia-Pacific shows rapid growth potential driven by aging populations and rising awareness. Emerging technologies like liquid biopsies and digital biomarkers are expected to reshape the landscape, offering scalable and cost-effective solutions for large-scale screening and personalized treatment approaches.
The global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size was estimated at USD 1678.28 million in 2024, exhibiting a CAGR of 8.75% during the forecast period.
This report provides a deep insight into the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market in any manner.
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AbaStar MDx
Abbott Laboratories
Abiant
Acumen Pharmaceuticals
Alseres Pharmaceuticals
Athena Diagnostics
Banyan Biomarkers
Bio-Rad Laboratories
Diagenic ASA
Immunarray Pvt
Myriad RBM
Proteome Sciences
ProteoSys AG
Psynova Neurotech
Qiagen
Quanterix Corporation
Thermo Fisher Scientific
Market Segmentation (by Type)
Genome
Proteome
Market Segmentation (by Application)
Hospital Laboratories
Research Organizations
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
Overview of the regional outlook of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Neurological biomarkers for Alzheimer's and Parkinson's diseases are measurable biological indicators that aid in the early detection, diagnosis, and monitoring of these neurodegenerative disorders. These biomarkers include proteins (e.g., amyloid-beta, tau, alpha-synuclein), genetic markers, cerebrospinal fluid (CSF) analytes, neuroimaging signals (e.g., PET scans, MRI), and blood-based markers. Their role is critical in differentiating between disease subtypes, assessing progression, and evaluating therapeutic efficacy, particularly as precision medicine gains traction in neurology. The demand for reliable, non-invasive biomarkers is accelerating due to the rising global prevalence of neurodegenerative diseases, the limitations of clinical symptom-based diagnosis, and the need for objective measures in clinical trials. Advances in proteomics, genomics, and AI-driven data analysis are expanding the scope of biomarker discovery, though challenges remain in standardization, validation, and regulatory approval. The market is driven by increasing R&D investments, collaborations between pharmaceutical companies and diagnostic firms, and growing emphasis on early intervention strategies. However, high development costs, ethical concerns around genetic testing, and variability in biomarker sensitivity and specificity pose barriers to widespread adoption. North America and Europe dominate the market due to robust healthcare infrastructure, while Asia-Pacific shows rapid growth potential driven by aging populations and rising awareness. Emerging technologies like liquid biopsies and digital biomarkers are expected to reshape the landscape, offering scalable and cost-effective solutions for large-scale screening and personalized treatment approaches.
The global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market size was estimated at USD 1678.28 million in 2024, exhibiting a CAGR of 8.75% during the forecast period.
This report provides a deep insight into the global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market in any manner.
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AbaStar MDx
Abbott Laboratories
Abiant
Acumen Pharmaceuticals
Alseres Pharmaceuticals
Athena Diagnostics
Banyan Biomarkers
Bio-Rad Laboratories
Diagenic ASA
Immunarray Pvt
Myriad RBM
Proteome Sciences
ProteoSys AG
Psynova Neurotech
Qiagen
Quanterix Corporation
Thermo Fisher Scientific
Market Segmentation (by Type)
Genome
Proteome
Market Segmentation (by Application)
Hospital Laboratories
Research Organizations
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
Overview of the regional outlook of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
171 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases
- 1.2 Key Market Segments
- 1.2.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Type
- 1.2.2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Estimates and Forecasts (2020-2033)
- 2.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Estimates and Forecasts (2020-2033)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Life Cycle
- 3.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Manufacturers (2020-2025)
- 3.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Competitive Situation and Trends
- 3.8.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
- 4.1 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market
- 5.7 ESG Ratings of Leading Companies
- 6 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Type (2020-2025)
- 6.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Market Share by Type (2020-2025)
- 6.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Price by Type (2020-2025)
- 7 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Sales by Application (2020-2025)
- 7.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) by Application (2020-2025)
- 7.4 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Growth Rate by Application (2020-2025)
- 8 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Sales by Region
- 8.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
- 8.1.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
- 8.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales Market Share by Region
- 8.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
- 8.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
- 8.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Market Share by Region
- 8.3 North America
- 8.3.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
- 8.3.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
- 8.4.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
- 8.5.2 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Country
- 8.6.2 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales by Region
- 8.7.2 Middle East and Africa Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Production by Region
- 9.1 Global Production of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Region(2020-2025)
- 9.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Revenue Market Share by Region (2020-2025)
- 9.3 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
- 9.4.1 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
- 9.4.2 North America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production
- 9.5.1 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
- 9.5.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
- 9.6.1 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
- 9.6.2 Japan Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production (2020-2025)
- 9.7.1 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production Growth Rate (2020-2025)
- 9.7.2 China Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 AbaStar MDx
- 10.1.1 AbaStar MDx Basic Information
- 10.1.2 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.1.3 AbaStar MDx Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.1.4 AbaStar MDx Business Overview
- 10.1.5 AbaStar MDx SWOT Analysis
- 10.1.6 AbaStar MDx Recent Developments
- 10.2 Abbott Laboratories
- 10.2.1 Abbott Laboratories Basic Information
- 10.2.2 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.2.3 Abbott Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.2.4 Abbott Laboratories Business Overview
- 10.2.5 Abbott Laboratories SWOT Analysis
- 10.2.6 Abbott Laboratories Recent Developments
- 10.3 Abiant
- 10.3.1 Abiant Basic Information
- 10.3.2 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.3.3 Abiant Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.3.4 Abiant Business Overview
- 10.3.5 Abiant SWOT Analysis
- 10.3.6 Abiant Recent Developments
- 10.4 Acumen Pharmaceuticals
- 10.4.1 Acumen Pharmaceuticals Basic Information
- 10.4.2 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.4.3 Acumen Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.4.4 Acumen Pharmaceuticals Business Overview
- 10.4.5 Acumen Pharmaceuticals Recent Developments
- 10.5 Alseres Pharmaceuticals
- 10.5.1 Alseres Pharmaceuticals Basic Information
- 10.5.2 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.5.3 Alseres Pharmaceuticals Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.5.4 Alseres Pharmaceuticals Business Overview
- 10.5.5 Alseres Pharmaceuticals Recent Developments
- 10.6 Athena Diagnostics
- 10.6.1 Athena Diagnostics Basic Information
- 10.6.2 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.6.3 Athena Diagnostics Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.6.4 Athena Diagnostics Business Overview
- 10.6.5 Athena Diagnostics Recent Developments
- 10.7 Banyan Biomarkers
- 10.7.1 Banyan Biomarkers Basic Information
- 10.7.2 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.7.3 Banyan Biomarkers Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.7.4 Banyan Biomarkers Business Overview
- 10.7.5 Banyan Biomarkers Recent Developments
- 10.8 Bio-Rad Laboratories
- 10.8.1 Bio-Rad Laboratories Basic Information
- 10.8.2 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.8.3 Bio-Rad Laboratories Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.8.4 Bio-Rad Laboratories Business Overview
- 10.8.5 Bio-Rad Laboratories Recent Developments
- 10.9 Diagenic ASA
- 10.9.1 Diagenic ASA Basic Information
- 10.9.2 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.9.3 Diagenic ASA Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.9.4 Diagenic ASA Business Overview
- 10.9.5 Diagenic ASA Recent Developments
- 10.10 Immunarray Pvt
- 10.10.1 Immunarray Pvt Basic Information
- 10.10.2 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.10.3 Immunarray Pvt Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.10.4 Immunarray Pvt Business Overview
- 10.10.5 Immunarray Pvt Recent Developments
- 10.11 Myriad RBM
- 10.11.1 Myriad RBM Basic Information
- 10.11.2 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.11.3 Myriad RBM Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.11.4 Myriad RBM Business Overview
- 10.11.5 Myriad RBM Recent Developments
- 10.12 Proteome Sciences
- 10.12.1 Proteome Sciences Basic Information
- 10.12.2 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.12.3 Proteome Sciences Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.12.4 Proteome Sciences Business Overview
- 10.12.5 Proteome Sciences Recent Developments
- 10.13 ProteoSys AG
- 10.13.1 ProteoSys AG Basic Information
- 10.13.2 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.13.3 ProteoSys AG Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.13.4 ProteoSys AG Business Overview
- 10.13.5 ProteoSys AG Recent Developments
- 10.14 Psynova Neurotech
- 10.14.1 Psynova Neurotech Basic Information
- 10.14.2 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.14.3 Psynova Neurotech Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.14.4 Psynova Neurotech Business Overview
- 10.14.5 Psynova Neurotech Recent Developments
- 10.15 Qiagen
- 10.15.1 Qiagen Basic Information
- 10.15.2 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.15.3 Qiagen Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.15.4 Qiagen Business Overview
- 10.15.5 Qiagen Recent Developments
- 10.16 Quanterix Corporation
- 10.16.1 Quanterix Corporation Basic Information
- 10.16.2 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.16.3 Quanterix Corporation Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.16.4 Quanterix Corporation Business Overview
- 10.16.5 Quanterix Corporation Recent Developments
- 10.17 Thermo Fisher Scientific
- 10.17.1 Thermo Fisher Scientific Basic Information
- 10.17.2 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Overview
- 10.17.3 Thermo Fisher Scientific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Product Market Performance
- 10.17.4 Thermo Fisher Scientific Business Overview
- 10.17.5 Thermo Fisher Scientific Recent Developments
- 11 Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Region
- 11.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast
- 11.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
- 11.2.3 Asia Pacific Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Region
- 11.2.4 South America Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Country
- 12 Forecast Market by Type and by Application (2026-2033)
- 12.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Type (2026-2033)
- 12.1.1 Global Forecasted Sales of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2033)
- 12.1.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size Forecast by Type (2026-2033)
- 12.1.3 Global Forecasted Price of Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases by Type (2026-2033)
- 12.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Forecast by Application (2026-2033)
- 12.2.1 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Sales (K Units) Forecast by Application
- 12.2.2 Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market Size (M USD) Forecast by Application (2026-2033)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.